

Symposium

New antimalarials: from drug discovery to clinical trials

December 19th 2022

9:00 – 9:20	Organizers		Opening
9:20 – 9:50	José Pedro Gil	Karolinska	Artemether/lumefantrine therapy is associated with <i>pfmdr-1</i> gene duplication in Africa
9:50 – 10:20	Anna Caroline Aguiar	Unifesp	From the bench to the field: ex vivo evaluation of new compounds against <i>Plasmodium vivax</i> and <i>P. falciparum</i> field isolates
10:20 – 11:00	Coffee Break		
11:00 – 11:30	Roberto Moraes Barros	Unifesp	Use of Nano-Luc expressing parasites in high-throughput screens for antimalarial drugs against <i>Plasmodium knowlesi</i> and <i>Plasmodium vivax</i>
11:30 – 12:00	Cornelis Winnips	Novartis	Ganaplacide/Lumefantrine-SDF, a next-generation treatment for acute malaria
12:00 – 13:30	Lunch		
13:30 – 14:00	Lise Musset	Pasteur Cayenne	Transmission and drug resistance capacities of <i>P. falciparum</i> in the Guiana Shield
14:00 – 14:30	Leonardo J. Carvalho	Fiocruz	Adjuvant therapies for cerebral malaria based on recovery of vascular function
14:30 – 14:50	Marcell Crispim	ICB/USP	The essential functions of isoprenoids as a tool for the discovery and potentiation of antimalarial compounds
14:50 – 15:40	Coffee Break		
15:40 – 16:00	Kim Williamson	USUHS	Targeting <i>P. falciparum</i> gametocytes to block malaria transmission
16:00 – 16:30	Igor Mota R. de Moura	USP	Discovery of inhibitors from Brazilian savana plants as lead compound candidates for malaria
16:30 – 17:00	Luiz Carlos Dias	Unicamp	The MINDI Consortium: Drug Discovery for the most Neglected

December 20th 2022

9:00 – 9:30	Glaucius Oliva	USP	Challenges and opportunities in drug discovery against infectious diseases
9:30 – 10:00	Brice Campo	MMV	Development of New Antimalarials focusing on <i>P. vivax</i> Liver Stage Hypnozoites
10:00 – 10:30	Leyre Pernaute	Karolinska	DHA/Piperaquine post treatment prophylaxis and drug resistance markers in Africa
10:30 – 11:00	Coffee Break		
11:00 – 11:30	Pedro Cravo	Nova Univ. of Lisbon	On the contribution of the rodent model <i>Plasmodium chabaudi</i> for understanding the genetics of drug resistance in malaria
11:30 – 12:00	David Fidock	Columbia Univ.	Genetic studies into <i>Plasmodium falciparum</i> determinants of resistance to first-line antimalarial drugs
12:00 – 13:30	Lunch		
13:30 – 14:00	Taís Nobrega de Souza	Karolinska	Current progress in pharmacogenetics of antimalarials used for the treatment of <i>Plasmodium vivax</i> malaria
14:00 – 14:30	Leticia Tiburcio	Columbia Univ.	Looking into 4-aminoquinolines as multistage antimalarials
14:30 – 14:50	Camila de Souza Barbosa	USP	Discovery of brussonol as a lead candidate for malaria
14:50 – 15:10	Camila Fabbri	Fiocruz	Implementation of new strategies to investigate transmission blocking compounds against <i>P. vivax</i>
15:10 – 15:30	Coffee Break		
15:30 – 16:00	Celia Garcia	USP	<i>Plasmodium falciparum</i> signaling pathways as targets of antimalarial drugs
16:00 – 16:30	Gustavo Cassiano	Nova Univ. of Lisbon	Discovery of potent antimalarial 1,4-naphthoquinones identified from computational screening
16:30 – 17:00	Dhelio Pereira	CEPEM	Antimalarials, the last two miles: clinical trial and implementation
17:00 – 17:10	Organizers		Closing